Drug Trial Radar · NCT00509873
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
Last checked: Nov 20, 2026Latest source record: Nov 30, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
578
Actual
Start
Aug 2007
Primary completion
Jun 2008
Study completion Jun 2008
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 1, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis
Conditions
- Bacterial Conjunctivitis
Interventions
Gatifloxacin 0.5% eye dropsDrug
Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
placebo eye dropsDrug
Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6Time frame: Day 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Gretna, Louisiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.